Hanmi Pharmaceuticals Co Ltd - Company Profile
Powered by 
All the data and insights you need on Hanmi Pharmaceuticals Co Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Hanmi Pharmaceuticals Co Ltd Strategy Report
- Understand Hanmi Pharmaceuticals Co Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Hanmi Pharmaceuticals Co Ltd (Hanmi Pharmaceuticals), a subsidiary of Hanmi Science Co Ltd, develops prescription drugs and over the counter (OTC) drugs. The company’s prescription drugs include antibiotics, antidiarrheal, drugs for osteoporosis, liver supplements, and antiemetics. It provides OTC products such as nutritional supplements, calcium supplement, and vitamins, among others. The products of Hanmi Pharmaceuticals are used in the treatment of cancer, depression, dementia, dermatology, diabetes, inflammation, cardiovascular conditions, epilepsy, hepatitis, osteoarthritis, gastrointestinal diseases, obesity, osteoporosis and others. The company operates manufacturing facilities in Hwaseong, Songpa and Pyeongtaek, South Korea. It supplies its products and APIs in various countries in Europe, Asia-Pacific and the Americas. Hanmi Pharmaceuticals is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
214, Muha-Ro, Paltan-Myeon, Hwaseong, Seoul, 18536
Website
www.hanmi.co.kr
Telephone
82 31 3505600
No of Employees
2,095
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
128940 (KRX)
Revenue (2022)
$1.1B
12%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
76.6%
(2022 vs 2021)
Market Cap*
$3.0B
Net Profit Margin (2022)
XYZ
57.7%
(2022 vs 2021)
* As of and is in US$
Hanmi Pharmaceuticals Co Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Prescription Drugs:- | Lapscovery |
| Antibiotics | Amosartan |
| Osteoporosis | Esomezol |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Plans/Strategy | In January, the company announced its plans to merge with OCI Group. |
| 2023 | Plans/Strategy | In August, the company announced its plans to enter into a partnership with Sanofi Co to develop the GLP-1 class Epeglenatide. |
| 2022 | New Products/Services | In December, the company launched "Bebe Goongdi Bubble Wash" a bubble wash lotion to clean baby skin. |
Competitor Comparison
| Key Parameters | Hanmi Pharmaceuticals Co Ltd | Yuhan Corp | GC Biopharma Corp | Daewoong Pharmaceutical Co Ltd | Dong-A Socio Holdings Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Hwaseong | Seoul | Yongin | Hwaseong | Seoul |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 2,095 | 1,594 | 1,766 | 1,256 | 273 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Young-Sook Song | Chairwoman | Executive Board | - | - |
| Jae-Hyun Park | Chief Executive Officer | Senior Management | - | - |
| Young Choi | Head - Research and Development Center | Senior Management | 2023 | 52 |
| Seo Gwi-hyeon | Director | Non Executive Board | - | - |
| Yeonggak Yoon | Director | Non Executive Board | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward